Clinical trials: BCC - Basal Cell Carcinoma
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Basal Cell Carcinoma, Squamous Cell Carcinoma
Photochemical Tissue Bonding
The broad aim of this study is to evaluate the efficacy of photochemical tissue bonding (PTB) for the closure of skin excisions.
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevus
- Trial name
- PTB (NCT00586040)
- Testing
- tissue bonding, sutures
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ
5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
The investigators will compare the application of two different creams for the treatment of low-risk skin cancers-superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis).
- Trial name
- NCT05381597
- Testing
- Combination cream of 5-fluorouracil and calcipotriene, 5-fluorouracil cream
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Boston University
Basal Cell Carcinoma
Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
Open-label, non-comparative, multicenter, phase II study of Vismodegib in patients with locally advanced BCC.
- Trial name
- VISMONEO (NCT02667574)
- Testing
- ERIVEDGE
- Where
- 17 sites in France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Lille
Head and Neck Cancer, Lung Cancer
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021333
- Testing
- filgrastim, cisplatin, paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Locally Advanced Basal Cell Carcinoma
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC.
- Trial name
- NCT07808515
- Testing
- Cemiplimab, Vidutolimod, Fianlimab
- Volunteers
- 135 people
- Sponsor
- Regeneron Pharmaceuticals
Nonmelanoma Skin Cancer, Basal Cell Carcinoma
Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)
This research study is for people who have been diagnosed with a nonmelanoma skin cancer (either basal cell carcinoma or squamous cell carcinoma) and are planning to receive either Mohs surgery or ED\&C (electrodessication \&…
- Conditions
- Nonmelanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- NCT07241585
- Testing
- Vitamin D (VitD), Photodynamic therapy (PDT), Mohs surgery or electrodessication & curettage (ED&C) (standard of care)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Case Comprehensive Cancer Center
Basal Cell Carcinoma, Chondrosarcoma
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
A treatment protocol that enables patients to have continued access to IPI-926.
- Trial name
- NCT01609179
- Testing
- IPI-926
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC)
Flash Radiotherapy for Skin Cancer
The goal of this clinical investigation is to describe and compare the toxicity and efficacy of an experimental radiotherapy, named FLASH therapy, to conventional radiotherapy for subjects suffering from localized Cutaneous…
- Trial name
- LANCE (NCT07455331)
- Testing
- FLASH radiotherapy, Conventional radiotherapy
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Jules Bordet Institute
Basal Cell Nevus Syndrome
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
Multicenter, double-blind, randomized, vehicle-controlled study that evaluates the efficacy and safety of patidegib gel 2% and 4% in comparison with vehicle in participants at least 18 years of age that meet the diagnostic…
- Trial name
- NCT02762084
- Testing
- Patidegib, Vehicle gel
- Where
- 2 sites in United Kingdom
- Volunteers
- 17 people
- Sponsor
- PellePharm, Inc.
Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
The primary objectives are to: 1. Evaluate the safety and tolerability of intralesional ASN-002 when administered in combination with oral vismodegib in patients with Basal Cell Carcinomas (BCC)s; 2.
- Trial name
- NCT04416516
- Testing
- ASN-002
- Where
- 7 sites in Australia
- Volunteers
- 21 people
- Sponsor
- Ascend Biopharmaceuticals Ltd
Actinic Keratosis, Basal Cell Carcinoma
Fractional CO2 Laser Assisted Photodynamic Therapy
Nodular Basal Cell Carcinomas: Compare the efficacy and safety of conventional versus fractional laser assisted PDT for difficult to treat nodular cell carcinomas in the face.
- Trial name
- NCT01260987
- Testing
- Conventional photodynamic therapy, Fractional CO2 laser assisted PDT
- Where
- Denmark
- Volunteers
- 47 people
- Sponsor
- Bispebjerg Hospital
Head and Neck Cancer, Lung Cancer
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Conditions
- Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006036
- Testing
- cisplatin, lurtotecan liposome
- Where
- 3 sites in Canada
- Volunteers
- 14 people
- Sponsor
- NCIC Clinical Trials Group
Locally Advanced Basal Cell Carcinoma
Tailored Sonidegib Schedule After Complete Response in BCC
Adult patients with locally advanced BCC, not amenable to surgical treatment and who obtained a complete response (CR) to Hedgehog inhibitors are administered a tailored schedule of the study drug.
- Trial name
- SONIBEC (NCT04806646)
- Testing
- Sonidegib
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Malignant Skin Melanoma T0, Basal Cell Carcinoma
DERM US and EU Validation Study
This study aims establish the effectiveness of Image Analysing Algorithm (DERM) to identify melanoma, Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) when used to analyse dermoscopic images of skin lesions within the…
- Conditions
- Malignant Skin Melanoma T0, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- NCT05126173
- Testing
- Deep Ensemble for the Recognition of Malignancy (DERM)
- Where
- 16 sites in United States, Italy
- Volunteers
- 1,111 people
- Sponsor
- Skin Analytics Limited
Melanoma, Basal Cell Carcinoma
The Impact of Total Body Skin Examination on Skin Cancer Detection
This will be a study where all patients will undergo a two-step procedure: Step 1 - Physicians examine the problem area of skin ONLY and record result. Step 2 - Physicians perform TBSE and record result.
- Conditions
- Melanoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Merkel Cell Carcinoma
- Trial name
- TBSE (NCT00765193)
- Testing
- Inspection of covered areas
- Where
- Austria
- Volunteers
- 14,381 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Squamous Cell Carcinoma, Basal Cell Carcinoma
Molecular Characterization of Cutaneous Tumors
The objective is to find genes which are responsible for the appearance of skin tumors (sCC, BCC) and it will be the basis for prediction of the disease and response to the treatment
- Trial name
- NCT03092830
- Testing
- Molecular testing of DNA/RNA from skin tumors, SCC/BCC
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Rabin Medical Center
Basal Cell Carcinoma
Rates of Positive Basal Cell Carcinomas (BCCs) in Re-excisions
Basal Cell Carcinoma (BCC) is the most common malignant growth in the world. Treatment is primarily surgical with the goal of excising the growth in its entirety.
- Trial name
- NCT01403480
- Volunteers
- 600 people
- Sponsor
- Rambam Health Care Campus
Basal Cell Carcinoma
The Role of Melanocyte in Basal Cell Carcinoma
Basal cell carcinoma (BCC) is the most frequent neoplasia worldwide. There are more than 30 histopathologic subtypes, however the nodular subtype is the most common.
- Trial name
- NCT02576769
- Testing
- No intervention
- Where
- Mexico
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT00023959
- Testing
- hydroxyurea, fluorouracil, bevacizumab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)